“Bimekizumab Safety in Patients with Psoriasis Achieving Complete Skin Clearance: 4-year Analysis from 5 Phase 3/3b Trials” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s757. doi:10.25251/v6wwxw80.